Irisin - a new biomarker for endometrial cancer?

OBJECTIVES

Irisin is an adipomyokine that has an inhibitory effect on inflammation and possesses anticancer activity. It inhibits cancer cell proliferation, metastasis, and invasion through various signaling pathways associated with carcinogenesis. It has been described to be associated with a number of malignancies in various locations. It has been recognized that it may be a biomarker and prognostic factor in some malignancies. In addition, studies indicate irisin's possible role in treating malignant lesions.

MATERIAL AND

METHODS

In material including 129 cases of endometrial cancer and normal endometrium in a control group of 18 women with uterine myomas.

RESULTS

There were no statistical differences in irisin protein expression. There were also no differences in irisin expression according to clinical stage, type, and histopathological differentiation.

CONCLUSIONS

Further clinical studies are needed to evaluate irisin activity in endometrial cancer.